BR112015002790A2 - anticorpos asgpr e usos dos mesmos. - Google Patents

anticorpos asgpr e usos dos mesmos.

Info

Publication number: BR112015002790A2
Authority: BR; Brazil
Prior art keywords: asgpr antibodies; asgpr; antibodies
Prior art date: 2012-08-09

Application number

BR112015002790A

Other languages

English (en)

Inventor

Ji Changhua

Moessner Ekkehard

Umana Pablo

Hofer Thomas

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-09

Filing date

2013-08-06

Publication date

2017-08-08

2013-08-06 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2017-08-08 Publication of BR112015002790A2 publication Critical patent/BR112015002790A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Toxicology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BR112015002790A 2012-08-09 2013-08-06 anticorpos asgpr e usos dos mesmos. BR112015002790A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261681239P	2012-08-09	2012-08-09
PCT/EP2013/066432 WO2014023709A1 (en)	2012-08-09	2013-08-06	Asgpr antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
BR112015002790A2 true BR112015002790A2 (pt)	2017-08-08

Family

ID=48917550

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112015002790A BR112015002790A2 (pt)	2012-08-09	2013-08-06	anticorpos asgpr e usos dos mesmos.

Country Status (11)

Country	Link
US (5)	US9771427B2 (pt)
EP (1)	EP2882775B1 (pt)
JP (3)	JP2015525792A (pt)
KR (1)	KR20150041626A (pt)
CN (2)	CN109705218B (pt)
BR (1)	BR112015002790A2 (pt)
CA (1)	CA2878626A1 (pt)
HK (1)	HK1211302A1 (pt)
MX (1)	MX2015001678A (pt)
RU (1)	RU2015107891A (pt)
WO (1)	WO2014023709A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9518087B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
BR112015002790A2 (pt)	2012-08-09	2017-08-08	Roche Glycart Ag	anticorpos asgpr e usos dos mesmos.
SG10201913952TA (en)	2013-09-11	2020-03-30	Eagle Biologics Inc	Liquid protein formulations containing viscosity-lowering agents
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
JP6744227B2 (ja) *	2014-02-21	2020-08-19	エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）ＥｃｏｌｅＰｏｌｙｔｅｃｈｎｉｑｕｅＦｅｄｅｒａｌｅｄｅＬａｕｓａｎｎｅ（ＥＰＦＬ）	糖標的化治療剤
EP3142691A4 (en) *	2014-05-16	2018-04-11	Baylor Research Institute	Methods and compositions for treating autoimmune and inflammatory conditions
SG11201702614SA (en)	2014-10-01	2017-04-27	Eagle Biolog Inc	Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
EP3344278A4 (en)	2015-09-04	2019-01-23	The California Institute for Biomedical Research	INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
JP7082045B2 (ja) *	2015-09-19	2022-06-07	エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）	糖標的化治療剤
EP4435105A2 (en) *	2015-09-29	2024-09-25	Amgen Inc.	Asgr inhibitors for reduzing cholesterol levels
US11993645B2 (en)	2017-01-11	2024-05-28	The Board Of Trustees Of The Leland Stanford Junior University	Compositions comprising R-Spondin (RSPO) surrogate molecules
CN110234662A (zh)	2017-01-26	2019-09-13	瑟罗泽恩公司	组织特异性wnt信号增强分子和其用途
EP3638296A1 (en)	2017-06-16	2020-04-22	The University Of Chicago	Compositions and methods for inducing immune tolerance
US11696572B2 (en) *	2017-06-27	2023-07-11	Regeneron Pharmaceuticals, Inc.	Non-human animals comprising a humanized ASGR1 locus
AU2019301633A1 (en) *	2018-07-09	2021-01-28	Surrozen Operating, Inc.	Tissue-specific Wnt signal enhancing molecules and uses
SG11202102777PA (en)	2018-09-27	2021-04-29	Xilio Development Inc	Masked cytokine polypeptides
US20220153801A1 (en) *	2019-03-28	2022-05-19	Orionis Biosciences, Inc.	Clec9a-based chimeric protein complexes
US20210130473A1 (en)	2019-10-09	2021-05-06	Silverback Therapeutics, Inc.	TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
KR102269748B1 (ko)	2019-10-31	2021-06-29	주식회사 에이스바이오메드	간세포 손상 표지자 아시알로 알파-1산 당단백질 측정을 통한 진행성 만성간염 및 간섬유화 정도 추적 진단용 키트 및 이의 용도
BR112022019689A2 (pt) *	2020-04-01	2022-12-20	Xilio Dev Inc	Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer
CA3184746A1 (en) *	2020-06-23	2021-12-30	Kadmon Corporation, Llc	Anti-pd-1 antibodies and fusion proteins
EP4175673A1 (en)	2020-07-01	2023-05-10	ARS Pharmaceuticals Inc.	Anti-asgr1 antibody conjugates and uses thereof
TWI815194B (zh)	2020-10-22	2023-09-11	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
US12024559B2 (en)	2020-10-23	2024-07-02	Asher Biotherapeutics, Inc.	Fusions with CD8 antigen binding molecules for modulating immune cell function
EP4243878A1 (en) *	2020-11-16	2023-09-20	Surrozen Operating, Inc.	Liver-specific wnt signal enhancing molecules and uses thereof
CA3219181A1 (en)	2021-05-19	2022-11-24	Yik Andy Yeung	Il-21 polypeptides and targeted constructs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4186567A (en)	1977-04-18	1980-02-05	Hitachi Metals, Ltd.	Ornament utilizing rare earth-cobalt magnet
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
KR950014915B1 (ko) *	1991-06-19	1995-12-18	주식회사녹십자	탈시알로당단백-포함화합물
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE503496T1 (de)	1992-02-06	2011-04-15	Novartis Vaccines & Diagnostic	Biosynthetisches bindeprotein für tumormarker
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
AU760562B2 (en)	1997-12-05	2003-05-15	Scripps Research Institute, The	Humanization of murine antibody
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
KR100797667B1 (ko)	1999-10-04	2008-01-23	메디카고 인코포레이티드	외래 유전자의 전사를 조절하는 방법
US7432063B2 (en)	2002-02-14	2008-10-07	Kalobios Pharmaceuticals, Inc.	Methods for affinity maturation
WO2005097832A2 (en)	2004-03-31	2005-10-20	Genentech, Inc.	Humanized anti-tgf-beta antibodies
KR100891620B1 (ko)	2004-04-13	2009-04-02	에프. 호프만-라 로슈 아게	항-ｐ-셀렉틴 항체
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
WO2009089004A1 (en)	2008-01-07	2009-07-16	Amgen Inc.	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2011020783A2 (en)	2009-08-17	2011-02-24	Roche Glycart Ag	Targeted immunoconjugates
US20130078216A1 (en)	2010-01-14	2013-03-28	Grainne Dunlevy	Liver targeting molecules
BR112015002790A2 (pt)	2012-08-09	2017-08-08	Roche Glycart Ag	anticorpos asgpr e usos dos mesmos.

2013
- 2013-08-06 BR BR112015002790A patent/BR112015002790A2/pt not_active IP Right Cessation
- 2013-08-06 US US14/419,824 patent/US9771427B2/en active Active
- 2013-08-06 RU RU2015107891A patent/RU2015107891A/ru not_active Application Discontinuation
- 2013-08-06 KR KR20157003176A patent/KR20150041626A/ko not_active Application Discontinuation
- 2013-08-06 CN CN201910108288.7A patent/CN109705218B/zh active Active
- 2013-08-06 MX MX2015001678A patent/MX2015001678A/es unknown
- 2013-08-06 CA CA2878626A patent/CA2878626A1/en not_active Abandoned
- 2013-08-06 JP JP2015525859A patent/JP2015525792A/ja not_active Ceased
- 2013-08-06 CN CN201380041685.8A patent/CN104704001B/zh active Active
- 2013-08-06 EP EP13745419.5A patent/EP2882775B1/en active Active
- 2013-08-06 WO PCT/EP2013/066432 patent/WO2014023709A1/en active Application Filing
2015
- 2015-12-08 HK HK15112087.2A patent/HK1211302A1/xx unknown
2017
- 2017-09-21 US US15/711,495 patent/US10087254B2/en active Active - Reinstated
2018
- 2018-01-23 JP JP2018008673A patent/JP6463522B2/ja active Active
- 2018-09-14 US US16/131,110 patent/US20190031760A1/en not_active Abandoned
- 2018-12-28 JP JP2018247659A patent/JP6929827B2/ja active Active
2019
- 2019-08-09 US US16/537,038 patent/US10975151B2/en active Active
2020
- 2020-11-23 US US17/102,112 patent/US20210324085A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2019088290A (ja)	2019-06-13
US10975151B2 (en)	2021-04-13
US20200102392A1 (en)	2020-04-02
MX2015001678A (es)	2015-08-14
CN104704001A (zh)	2015-06-10
EP2882775A1 (en)	2015-06-17
HK1211302A1 (en)	2016-05-20
US20210324085A1 (en)	2021-10-21
JP6463522B2 (ja)	2019-02-06
CN109705218A (zh)	2019-05-03
US20150299324A1 (en)	2015-10-22
US9771427B2 (en)	2017-09-26
CN104704001B (zh)	2019-02-12
US10087254B2 (en)	2018-10-02
JP6929827B2 (ja)	2021-09-01
JP2015525792A (ja)	2015-09-07
KR20150041626A (ko)	2015-04-16
EP2882775B1 (en)	2018-02-14
JP2018093880A (ja)	2018-06-21
CN109705218B (zh)	2022-07-19
RU2015107891A (ru)	2016-09-27
US20190031760A1 (en)	2019-01-31
WO2014023709A1 (en)	2014-02-13
CA2878626A1 (en)	2014-02-13
US20180118833A1 (en)	2018-05-03

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-05-29	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 5A ANUIDADE.
2018-10-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BR112015002790A2 (pt)	2017-08-08	anticorpos asgpr e usos dos mesmos.
BR112015001459A2 (pt)	2017-07-04	anticorpos anti-kit e usos dos mesmos.
CL2015001924A1 (es)	2016-06-10	Anticuerpos anti-pdgfr-beta y usos relacionados.
BR112015014063A2 (pt)	2018-10-30	anticorpos anti-b7-h4 humano e seus usos.
CL2015000027A1 (es)	2015-07-10	Anticuerpos e inmunoconjugados anti-cd22
CL2016000251A1 (es)	2017-07-14	Anticuerpos anti-activina y usos de los mismos
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
CL2014002416A1 (es)	2015-01-16	Anticuerpos humanos anti-cd27, métodos y usos
CO7071096A2 (es)	2014-09-30	Anticuerpos anti-lgr5 e inmunoconjugados
BR112014029403A2 (pt)	2018-10-09	conjugados, anticorpo e formulação farmacêutica
BR112014030278A2 (pt)	2017-06-27	anticorpo, e, composição.
BR112015002193A2 (pt)	2017-07-04	anticorpos anti-etbr e imunoconjugados
BR112013007499A2 (pt)	2016-07-12	piridazinonas - métodos de criação e usos
BR112014027730A2 (pt)	2017-08-08	material, e material não tecido
BR112015009932A2 (pt)	2017-07-11	método e sistema.
DK3117837T3 (da)	2019-08-19	Antistofformuleringer
DK2858676T3 (da)	2019-05-13	Prostata-specifikke membran-antigen-antistof-lægemiddelkonjugater
BR112015004817A2 (pt)	2017-07-04	bioconjugados compreendendo antígenos modificados e seus usos
BR112014000317A2 (pt)	2018-06-19	conjunto e sistema
BR112015003259A2 (pt)	2017-08-08	composto, composição farmacêutica, e, composição de vacina.
BR112013014235A2 (pt)	2016-09-27	anticorpos anti-ccr4 e usos dos mesmos
CL2014002019A1 (es)	2015-01-16	Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
BR112014026357A2 (pt)	2017-06-27	composição e sistema
BR112015001224A2 (pt)	2017-07-04	sistema de amortecimento e turbina
BR112014028921A2 (pt)	2018-05-22	injetor.